R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 49.6 CNY -4.39% Market Closed
Market Cap: 4.8B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

R&G PharmaStudies Co Ltd
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Common Shares Outstanding
ÂĄ96m
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Common Shares Outstanding
ÂĄ2.9B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Common Shares Outstanding
ÂĄ1.8B
CAGR 3-Years
15%
CAGR 5-Years
22%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Common Shares Outstanding
ÂĄ4.2B
CAGR 3-Years
-1%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Common Shares Outstanding
ÂĄ861.5m
CAGR 3-Years
0%
CAGR 5-Years
3%
CAGR 10-Years
3%
W
WuXi XDC Cayman Inc
HKEX:2268
Common Shares Outstanding
ÂĄ1.2B
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
4.8B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
59.36 CNY
Undervaluation 16%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Common Shares Outstanding?
Common Shares Outstanding
96m CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Common Shares Outstanding amounts to 96m CNY.

What is R&G PharmaStudies Co Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 3Y
17%

Over the last year, the Common Shares Outstanding growth was 0%. The average annual Common Shares Outstanding growth rates for R&G PharmaStudies Co Ltd have been 17% over the past three years .

Back to Top